Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
4.7
Journals
Biomedicines
Special Issues
Chronic Inflammatory Skin Diseases: From Bench to Bedside
share announcement

Chronic Inflammatory Skin Diseases: From Bench to Bedside

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Immunology and Immunotherapy".

Deadline for manuscript submissions: closed (16 May 2023) | Viewed by 7112

Special Issue Editor

Dr. Alexandra Maria Giovanna Brunasso

E-Mail Website
Guest Editor
Villa Scassi Hospital, Genoa, Italy
Interests: psoriasis; biologic therapies; plamoplantar pustulosis; hidradenitis suppurativa

Special Issue Information

Dear Colleagues,

Chronic inflammatory skin diseases represent the largest class of chronic skin conditions, being a major issue not only in dermatology but also in general medicine. This Special Issue is dedicated to discussing the latest research, developments and new ideas from bench to bedside. We would like to offer new perspectives regarding diagnosis, clinical manifestations and therapeutic approach to chronic inflammatory skin diseases such as psoriasis, hidradenitis suppurativa, atopic dermatitis, autoimmune bullous and non-bullous diseases.

Despite undisputed achievements over the last few decades, we still do not fully understand all of these diseases. The complexity of the immunological background, the clinical heterogeneity and the presence of several comorbidities, including metabolic syndrome, cardiovascular diseases and others, make our everyday clinical practice a challenge.

We look forward to receiving your best original research and review papers.

Dr. Alexandra Maria Giovanna Brunasso
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • inflammatory diseases
  • atopic dermatitis
  • psoriasis
  • bullous diseases
  • autoimmune skin diseases
  • biological therapy
  • genetics
  • immunology
  • biomarkers

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

Jump to: Other

33 pages, 2275 KiB  
Review
Exploring the Pathogenesis and Mechanism-Targeted Treatments of Rosacea: Previous Understanding and Updates
by Chengqian Chen, Peiru Wang, Linglin Zhang, Xiaojing Liu, Haiyan Zhang, Yajing Cao, Xiuli Wang and Qingyu Zeng
Biomedicines 2023, 11(8), 2153; https://doi.org/10.3390/biomedicines11082153 - 31 Jul 2023
Cited by 3 | Viewed by 4534
Abstract
Rosacea is a chronic inflammatory skin disease characterized by recurrent erythema, flushing, telangiectasia, papules, pustules, and phymatous changes in the central area of the face. Patients with this condition often experience a significant negative impact on their quality of life, self-esteem, and overall [...] Read more.
Rosacea is a chronic inflammatory skin disease characterized by recurrent erythema, flushing, telangiectasia, papules, pustules, and phymatous changes in the central area of the face. Patients with this condition often experience a significant negative impact on their quality of life, self-esteem, and overall well-being. Despite its prevalence, the pathogenesis of rosacea is not yet fully understood. Recent research advances are reshaping our understanding of the underlying mechanisms of rosacea, and treatment options based on the pathophysiological perspective hold promise to improve patient outcomes and reduce incidence. In this comprehensive review, we investigate the pathogenesis of rosacea in depth, with a focus on emerging and novel mechanisms, and provide an up-to-date overview of therapeutic strategies that target the diverse pathogenic mechanisms of rosacea. Lastly, we discuss potential future research directions aimed at enhancing our understanding of the condition and developing effective treatments. Full article
(This article belongs to the Special Issue Chronic Inflammatory Skin Diseases: From Bench to Bedside)
►▼ Show Figures

Figure 1

Other

Jump to: Review

15 pages, 6092 KiB  
Case Report
Risankizumab: Daily Practice Experience of High Need Patients
by Alexandra M. G. Brunasso, Martina Burlando, Fabrizio Amoruso, Luisa Arancio, Giovanna Malara, Raffaella Manzo, Maria Antonia Montesu and Giacomo Caldarola
Biomedicines 2023, 11(6), 1769; https://doi.org/10.3390/biomedicines11061769 - 20 Jun 2023
Cited by 2 | Viewed by 2039
Abstract
Psoriasis is a chronic inflammatory disease which affects 29.5 million people worldwide and it can negatively impact quality of life, especially when it affects a special localization, such as nails, face, palms and soles, or intertriginous regions. Risankizumab is a humanized monoclonal antibody [...] Read more.
Psoriasis is a chronic inflammatory disease which affects 29.5 million people worldwide and it can negatively impact quality of life, especially when it affects a special localization, such as nails, face, palms and soles, or intertriginous regions. Risankizumab is a humanized monoclonal antibody which targets the p19 subunit of interleukin-23 and it is currently licensed also as systemic therapy for moderate to severe plaque psoriasis. Here, we present eight cases of patients with moderate to severe psoriasis treated with risankizumab with a significant efficacy in the remission of the disease. Our cases represent a real-world clinical setting and provide a valuable adjunct to results obtained in the selected patients usually included in controlled clinical trials. In our cases, risankizumab rapidly improved clinical manifestations and relieved symptoms in patients with moderate to severe psoriasis, regardless of the presence of comorbidities or the location of the plaques in special sites, and without any safety concerns. Full article
(This article belongs to the Special Issue Chronic Inflammatory Skin Diseases: From Bench to Bedside)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop